Luxembourg based 3B Future Health GP S.a.r.l. has launched its second fund focused on early stage investment opportunities in areas of high unmet patient need.
3B Future Health Fund II, which follows 3B Future Health Fund I, formerly known as Helsinn Investment Fund, is led by General Partners Riccardo Braglia, Francesco Giavatto, Francesco Granata and Roberto De Ponti, who together bring expertise in drug discovery and research and development, drug manufacturing, business development and licensing as well as investment fund management.
The fund’s investment focus is on US and European-based startups working in the field of oncology and rare diseases therapeutics.
The vehicle is incorporated in Luxembourg where the anchor investors will be the Helsinn Group and the Braglia family and targets €100M partnering with experienced private and institutional investors.